Simmaron’s COVID-19 Emergency Actions

You are here: Simmaron ResearchSimmaron’s COVID-19 Emergency Actions

Simmaron Responds to COVID-19 Health Emergency!

Testing, testing, testing: Simmaron fills an urgent community need for COVID-19 testing in the Tahoe area, working in collaboration with long-time partner Coppe Laboratories in Wisconsin. Essential workers, patients and the Tahoe community benefit from wider testing.

Simmaron Research’s clinical research team, in partnership with Coppe Laboratories (Waukesha, WI), is conducting comprehensive COVID-19 testing under the auspices of a new formal Emergency Use Authorization (EUA) from the Food and Drug Administration. The EUA permits sample collection for both the rapid polymerase chain reaction test (PCR), and Immunoglobulin G (IgG) antibody test for COVID-19. The PCR based assay identifies active infection, while the IgG antibody test identifies the immune signature that is associated with previous exposure.

Post-viral Research is our thing: Simmaron’s work on COVID-19 testing will also provide a research bridge to link longtime post-viral ME/CFS research with a new viral pandemic that poses the unfortunate prospect of inflicting many more patients with chronic, post-viral disease. We have so much to learn from each other: as we study post-COVID recovery, new post-viral patients can learn from long-time post-viral patients and vice versa.

ME/CFS is a debilitating disease that often follows infections, including influenza, mononucleosis, coxsackie, SARS and MERS. NIH is conducting a comprehensive intramural study on post-infectious ME/CFS.

Post-infectious ME/CFS is at the core of Simmaron’s decade-long record of research. We have published more than 20 peer-reviewed manuscripts documenting immune aberrations, patient subsets, and treatment pilots in ME/CFS. Our signature research studies evaluate immune abnormalities in ME/CFS spinal fluid. Our collaborators include U.S. Centers for Disease Control, National Institutes of Health, Columbia University’s Center for Infection and Immunity, Cornell University, SUNY Albany, Coppe Laboratories, and more.

Post-COVID disease? While we need as much scientific research as possible on the acute phase of the COVID-19 pandemic, we also need research documenting the progression and recovery rates of COVID patients. Simmaron will seek to study disease trajectory in our community to learn from every stage of this viral pandemic.